Phenotypes associated with this allele

• Allele Symbol: Krt19^{tm1(cre/ERT)Ggu}
• Allele Name: targeted mutation 1, Guoqiang Gu
• Allele ID: MGI:3797107
• Summary: 5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Krt19^tm1(cre/ERT)Ggu/Krt19^tm1(cre/ERT)Ggu	involves: C57BL/6 * CD-1	MGI:5056453
cn2	Gt(ROSA)26Sor^tm1(Neurog3*S183A*S187A)Axbe/? Krt19^tm1(cre/ERT)Ggu/?	B6.Cg-Gt(ROSA)26Sor^tm1(Neurog3*S183A*S187A)Axbe Krt19^tm1(cre/ERT)Ggu	MGI:5605023
cn3	Kras^tm4Tyj/Kras^+ Trp53^tm1Brn/Trp53^tm1Brn Krt19^tm1(cre/ERT)Ggu/Krt19^+	involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac	MGI:5298083
cn4	Kras^tm4Tyj/Kras^+ Krt19^tm1(cre/ERT)Ggu/Krt19^+ Pten^tm2Mak/Pten^tm2Mak	involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac	MGI:6256734
cn5	Kras^tm4Tyj/Kras^+ Krt19^tm1(cre/ERT)Ggu/Krt19^+	involves: 129S4/SvJae * 129S6/SvEvTac	MGI:5298082

Genotype
MGI:5056453

hm1

• Allelic Composition: Krt19^{tm1(cre/ERT)Ggu}/Krt19^{tm1(cre/ERT)Ggu}
• Genetic Background: involves: C57BL/6 * CD-1

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:136694 )

• authors state that Krt19 is non-essential for viability; homozygous Krt19 animals carrying the R26-YFP reporter are used for lineage tracing, indicating that homozygotes are viable

Genotype
MGI:5605023

cn2

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Neurog3*S183A*S187A)Axbe}/?; Krt19^{tm1(cre/ERT)Ggu}/?
• Genetic Background: B6.Cg-Gt(ROSA)26Sor^{tm1(Neurog3*S183A*S187A)Axbe} Krt19^{tm1(cre/ERT)Ggu}

endocrine/exocrine glands

increased pancreatic beta cell number ( J:215154 )

• 13 days after tamoxifen injection, a greater proportion of insulin-immunostaining duct cells are observed in pancreas sections from 6-9 week old mice bearing both the conditional Neurog3 knock-in and a pancreatic duct-specific cre recombinase/estrogen receptor fusion knock-in allele than in sections from control mice with only the conditional allele (highly significant at p = 0.0042 (<= 0.01) by Student's unpaired t test).

Genotype
MGI:5298083

cn3

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Trp53^tm1Brn/Trp53^tm1Brn; Krt19^{tm1(cre/ERT)Ggu}/Krt19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac

mortality/aging

lethality, complete penetrance ( J:172048 )

• tamoxifen treated mice die within 2 months from intestinal cancers before developing skin tumors

digestive/alimentary system

increased gastrointestinal tumor incidence ( J:172048 )

• tamoxifen treated mice develop intestinal cancers

neoplasm

increased gastrointestinal tumor incidence ( J:172048 )

• tamoxifen treated mice develop intestinal cancers

increased skin tumor incidence ( J:172048 )

• when back skin from mutant animals is grafted onto back skin of nude mice, all engrafted mice develop skin tumors, including ulcerative lesions (benign and squamous cell carcinomas) within 2 months of tamoxifen administration

increased carcinoma incidence ( J:172048 )

• tamoxifen treated mice develop terminal intestinal carcinomas with 2 months of treatment

integument

increased skin tumor incidence ( J:172048 )

• when back skin from mutant animals is grafted onto back skin of nude mice, all engrafted mice develop skin tumors, including ulcerative lesions (benign and squamous cell carcinomas) within 2 months of tamoxifen administration

Genotype
MGI:6256734

cn4

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Krt19^{tm1(cre/ERT)Ggu}/Krt19⁺; Pten^tm2Mak/Pten^tm2Mak
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac

mortality/aging

premature death ( J:254370 )

• mice administered tamoxifen at 8 weeks of age show a median survival of 30 days after tamoxifen injection

digestive/alimentary system

abnormal colon morphology ( J:254370 )

• colonic serrated epithelial changes in tamoxifen treated mice

stomach mucosa hyperplasia ( J:254370 )

• hyperplastic changes of gastric mucosa in tamoxifen treated mice

endocrine/exocrine glands

abnormal extrahepatic bile duct morphology ( J:254370 )

• extrahepatic bile duct is rigid and dilated in tamoxifen treated mice

• papillary hyperplasia of the extrahepatic biliary tract

abnormal gallbladder morphology ( J:254370 )

• papillary hyperplasia of the gallbladder in tamoxifen treated mice

abnormal cystic duct morphology ( J:254370 )

• gallbladder and cystic duct are rigid and dilated in tamoxifen treated mice

dilated gallbladder ( J:254370 )

• in tamoxifen treated mice

increased pancreatic intraepithelial neoplasia incidence ( J:254370 )

• PanIN-like lesions and hyperplasia in the pancreatic ducts in tamoxifen treated mice

• however, no obvious tumors are seen in mice administered tamoxifen at 8 weeks of age

immune system

lung inflammation ( J:254370 )

• obstructive pneumonia in tamoxifen treated mice

liver/biliary system

abnormal extrahepatic bile duct morphology ( J:254370 )

• extrahepatic bile duct is rigid and dilated in tamoxifen treated mice

• papillary hyperplasia of the extrahepatic biliary tract

abnormal gallbladder morphology ( J:254370 )

• papillary hyperplasia of the gallbladder in tamoxifen treated mice

abnormal cystic duct morphology ( J:254370 )

• gallbladder and cystic duct are rigid and dilated in tamoxifen treated mice

dilated gallbladder ( J:254370 )

• in tamoxifen treated mice

abnormal liver morphology ( J:254370 )

• liver of tamoxifen treated mice shows pre-malignant papillary ductal lesions in periportal areas

neoplasm

increased pancreatic intraepithelial neoplasia incidence ( J:254370 )

• PanIN-like lesions and hyperplasia in the pancreatic ducts in tamoxifen treated mice

• however, no obvious tumors are seen in mice administered tamoxifen at 8 weeks of age

respiratory system

lung inflammation ( J:254370 )

• obstructive pneumonia in tamoxifen treated mice

bronchial epithelial hyperplasia ( J:254370 )

• papillary hyperplasia of bronchial epithelia in tamoxifen treated mice

respiratory failure ( J:254370 )

• respiratory failure by lung lesions in tamoxifen treated mice

Genotype
MGI:5298082

cn5

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Krt19^{tm1(cre/ERT)Ggu}/Krt19⁺
• Genetic Background: involves: 129S4/SvJae * 129S6/SvEvTac

neoplasm

increased lip tumor incidence ( J:172048 )

• 2-4 months after tamoxifen treatment, lip tumors develop in 78% of treated mice

increased skin tumor incidence ( J:172048 )

• 2-4 months after tamoxifen treatment, tumors develop in the back skin in 33% of treated mice

increased skin papilloma incidence ( J:172048 )

• skin tumors are benign papillomas with no sign of malignant transformation seen up to 4 months after treatment with tamoxifen

craniofacial

increased lip tumor incidence ( J:172048 )

• 2-4 months after tamoxifen treatment, lip tumors develop in 78% of treated mice

growth/size/body

increased lip tumor incidence ( J:172048 )

• 2-4 months after tamoxifen treatment, lip tumors develop in 78% of treated mice

integument

abnormal skin sebaceous gland morphology ( J:172048 )

• sebaceous cyst formation is observed as result of bulge stem cell proliferation and abnormal hair follicle (HF) differentiation

enlarged sebaceous gland ( J:172048 )

• 1 month after tamoxifen treatment, Kras activation results in the enlargement of the majority of sebaceous glands

sebaceous gland hyperplasia ( J:172048 )

increased hair follicle cell proliferation ( J:172048 )

• 1 month after tamoxifen treatment, Kras activation results in transient increase in hair follicle bulge stem cell (SC) proliferation

• hyperproliferative bulge SCs can still undergo terminal differentiation

increased skin tumor incidence ( J:172048 )

• 2-4 months after tamoxifen treatment, tumors develop in the back skin in 33% of treated mice

increased skin papilloma incidence ( J:172048 )

• skin tumors are benign papillomas with no sign of malignant transformation seen up to 4 months after treatment with tamoxifen

endocrine/exocrine glands

abnormal skin sebaceous gland morphology ( J:172048 )

• sebaceous cyst formation is observed as result of bulge stem cell proliferation and abnormal hair follicle (HF) differentiation

enlarged sebaceous gland ( J:172048 )

• 1 month after tamoxifen treatment, Kras activation results in the enlargement of the majority of sebaceous glands

sebaceous gland hyperplasia ( J:172048 )

cellular

increased cell proliferation ( J:172048 )

• 1 month after tamoxifen treatment, Kras activation results in transient increase in hair follicle bulge stem cell (SC) proliferation